17,261 trials
Adductor Spasmodic Dysphonia · Voice Disorders · Spasmodic Dysphonia
Primary: Our Primary Outcome is the Difference in VHI-10 Score at 30 Days After Injection With DAXI. — 17.81 units on a scale — p=<0.001
Chronic Low-back Pain
Primary: Incidence of Adverse Events — 3; 15; 18 Participants
Non-Small Cell Lung Cancer (NSCLC)
Primary: Overall Response Rate (ORR) Per RECIST v1.1 by BIRC Assessment — 53.3; 38.1 percentage of participants
Tinnitus
Primary: GABA and Glutamate (Glx) Levels in the Auditory Cortex Derived From 3T Magnetic Resonance Spectroscopy — 2.11; 2.12; 2.09; 2.03 Ratio — p=0.05
Relapsed Diffuse Large B-cell Lymphoma · Refractory Diffuse Large B-cell Lymphoma
Primary: Overall Response Rate (ORR) — 46.2 percentage of participants — p=0.0044
Nonalcoholic Fatty Liver Disease · Nonalcoholic Steatohepatitis
Primary: Relative Change in Alanine Aminotransferase (ALT) From Baseline to 24 Weeks — -38.4; -36.3; -36.4; -12.2 % change — p=<0.0001
Abdominal Surgery · Colon Surgery · Post-Op Infection
Primary: The Combined Infection and Mortality Rate Within 30 Days Post Index Surgery — 24; 10 Participants — p=0.0086
Severe Hypertriglyceridemia
Primary: Percent Change From Baseline at Week 24 in Fasting Triglycerides (TG) — -17.2; -66.0; -70.2; -74.2 percentage change — p=< 0.0001
Hepatocellular Carcinoma (HCC)
Primary: Objective Response Rate (ORR) According to RECIST 1.1 — 4 Participants
Stress
Primary: Between-Arm Difference in Change in Ecological Momentary Assessment (EMA) of Stress. — -0.50; -0.31 units on a scale — p=.316
Asthma · Obesity
Primary: Percentage of Neutrophils in Peripheral Blood — 57.3; 55.4 percentage of neutrophils — p=0.53
Kidney Transplantation
Primary: Percentage of Participants With Composite Efficacy Failure Event (Biopsy Proven Acute Rejection (BPAR), Graft Loss or Death) Over 12 Months Post-transplantation (Cohort…
HER2 Positive Breast Carcinoma · Stage I Breast Cancer AJCC v7 · Stage IA Breast Cancer AJCC v7
Primary: Number Participants With Neutropenia, Graded According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version (v)4.03 — 2…
Parkinson's Disease
Primary: Change From Baseline to Week 12 on the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II + Part III — -2.81; -2.09 score on a…
Bacteremia · Staphylococcus Aureus · Staphylococcus Aureus Bacteremia
Primary: Number of Participants With Treatment-Emergent Adverse Events (Safety and Tolerability) Following Multiple Doses of Intravenous AP-Sa02. — 17; 10; 6; 2 number of…